FDA+ roundup: Agency reopens AI discussion paper for comments amid two-day workshop

The FDA is re­open­ing the com­ment pe­ri­od on its dis­cus­sion pa­per on us­ing ar­ti­fi­cial in­tel­li­gence in drug de­vel­op­ment, co­in­cid­ing with a two-day work­shop on the top­ic.

The agency in March pub­lished a dis­cus­sion pa­per on the use of AI in drug de­vel­op­ment, which laid out con­sid­er­a­tions and po­ten­tial ar­eas for pol­i­cy de­vel­op­ment in that area. The orig­i­nal com­ment pe­ri­od end­ed on May 1, but the FDA on Tues­day re­opened it for an­oth­er 60 days to al­low for more com­ments fol­low­ing its two-day work­shop on the top­ic be­ing held Tues­day and Wednes­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.